Therefore, one of the most important questions of recent times is whether late geographic atrophy is really more prevalent in patients with long-term anti-VEGF use, and if so, what role the anti-VEGF agents play in the development of geographic atrophy. The gene discussed is VEGFA; the disease is atrophic macular degeneration.